RU2015127794A - Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в - Google Patents

Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в Download PDF

Info

Publication number
RU2015127794A
RU2015127794A RU2015127794A RU2015127794A RU2015127794A RU 2015127794 A RU2015127794 A RU 2015127794A RU 2015127794 A RU2015127794 A RU 2015127794A RU 2015127794 A RU2015127794 A RU 2015127794A RU 2015127794 A RU2015127794 A RU 2015127794A
Authority
RU
Russia
Prior art keywords
introduction
antisense oligonucleotides
oligonucleotides complementary
human apolipoprotein
antisense oligonucleotide
Prior art date
Application number
RU2015127794A
Other languages
English (en)
Inventor
Ричард С. ГИРИ
Чжэнжун ЮЙ
Марк К. ВЕДЕЛЬ
Дайан Триббл
Original Assignee
Касл Терапьютикс, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Касл Терапьютикс, ЭлЭлСи filed Critical Касл Терапьютикс, ЭлЭлСи
Publication of RU2015127794A publication Critical patent/RU2015127794A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Claims (1)

  1. Способ, включающий в себя введение субъекту фармацевтической композиции, включающей в себя антисмысловой олигонуклеотид, комплементарный нуклеиновой кислоте, кодирующей человеческий аполипопротеин В-100, в котором введение включает в себя фазу индукции, во время которой вводят дозу антисмыслового олигонуклеотида в пределах 100-300 мг один раз в неделю в течение по меньшей мере 13 недель, с последующей поддерживающей фазой, во время которой вводят дозу антисмыслового олигонуклеотида в пределах 80-200 мг один раз в неделю или один раз в две недели в течение такого периода времени, который является необходимым, эффективным и/или переносимым.
RU2015127794A 2007-03-24 2008-03-24 Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в RU2015127794A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89691407P 2007-03-24 2007-03-24
US60/896,914 2007-03-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2009139221/10A Division RU2559536C2 (ru) 2007-03-24 2008-03-24 Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в

Publications (1)

Publication Number Publication Date
RU2015127794A true RU2015127794A (ru) 2018-12-21

Family

ID=39561976

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015127794A RU2015127794A (ru) 2007-03-24 2008-03-24 Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
RU2009139221/10A RU2559536C2 (ru) 2007-03-24 2008-03-24 Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2009139221/10A RU2559536C2 (ru) 2007-03-24 2008-03-24 Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в

Country Status (14)

Country Link
US (2) US9347061B2 (ru)
EP (1) EP2137311A1 (ru)
JP (3) JP2010522245A (ru)
KR (2) KR20150090284A (ru)
CN (2) CN101679979A (ru)
AU (1) AU2008230886B9 (ru)
BR (1) BRPI0809320A2 (ru)
CA (1) CA2682082A1 (ru)
CO (1) CO6241170A2 (ru)
IL (1) IL201183A0 (ru)
MX (1) MX2009010196A (ru)
RU (2) RU2015127794A (ru)
WO (1) WO2008118883A1 (ru)
ZA (1) ZA200906772B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
AU2007258117B2 (en) 2006-05-05 2013-05-30 Isis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
KR20150090284A (ko) * 2007-03-24 2015-08-05 젠자임 코포레이션 인간 아포리포프로틴 ｂ에 상보적인 안티센스 올리고뉴클레오타이드 투여
ES2616051T3 (es) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo
EP2408796B1 (en) 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
EP2488210A4 (en) 2009-10-12 2014-04-30 Smith Holdings Llc METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
US20150038549A1 (en) 2011-04-20 2015-02-05 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Components That Self Assemble in Cells and Produce RNAi Activity
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
CN107011400B (zh) 2012-07-13 2021-05-25 波涛生命科学有限公司 不对称辅助基团
MX2015000577A (es) 2012-07-13 2015-08-14 Wave Life Sciences Pte Ltd Control quiral.
EP2920304B1 (en) 2012-11-15 2019-03-06 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
AU2014222150A1 (en) * 2013-03-01 2015-09-10 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
WO2015191179A1 (en) * 2014-05-02 2015-12-17 Baruch S. Blumberg Institute Ttp inhibitiors of low density lipprotein secretion for the management of diseases associated with elevated blood ldl levels
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
UA123355C2 (uk) * 2015-03-13 2021-03-24 Есперіон Терапеутікс, Інк. Фіксовані комбінації й склади, які містять etc-1002 й езетиміб, і способи лікування або зменшення ризику розвитку серцево-судинного захворювання
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP3271405A1 (en) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
US20170014477A1 (en) * 2015-05-01 2017-01-19 The Trustees Of Columbia University In The City Of New York Free raptor reduces aging- and obesity-induced fatty liver
RU2596497C1 (ru) * 2015-09-07 2016-09-10 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" (ФГАОУ ВО "КФУ им. В.И. Вернадского") Способ прогнозирования приверженности к лечению физическими нагрузками больных артериальной гипертензией
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2023177242A1 (ko) * 2022-03-17 2023-09-21 주식회사 에이치피바이오 아포지단백 b100에 특이적으로 결합하는 dna 앱타머 및 상기 dna 앱타머의 용도

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712257A (en) * 1987-08-12 1998-01-27 Hem Research, Inc. Topically active compositions of mismatched dsRNAs
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US6852536B2 (en) 2001-12-18 2005-02-08 Isis Pharmaceuticals, Inc. Antisense modulation of CD36L 1 expression
US5220006A (en) * 1990-10-23 1993-06-15 The United States Of America As Represented By The Department Of Health And Human Services Identification of a suppressor of atherogenic apolipoprotein
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
WO1992010590A1 (en) 1990-12-10 1992-06-25 Gilead Sciences, Inc. Inhibition of transcription by formation of triple helixes
US5604115A (en) 1990-12-21 1997-02-18 The Rockefeller University Liver enriched transcription factor
US5965722A (en) 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US5578444A (en) 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
US5877009A (en) 1991-08-16 1999-03-02 Trustees Of Boston University Isolated ApoA-I gene regulatory sequence elements
DE4129653A1 (de) 1991-09-06 1993-03-11 Boehringer Mannheim Gmbh Verfahren zum nachweis aehnlicher nukleinsaeuren
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
JPH07502414A (ja) * 1991-12-23 1995-03-16 バイエル　コーポレイション 溶液相サンドイッチハイブリダイゼーションアッセイに用いるためのクラミジアプローブ
US6180403B1 (en) 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
WO1994013794A1 (en) 1992-12-04 1994-06-23 Brigham And Women's Hospital, Inc. Human thrombospondin-4
US5434058A (en) * 1993-02-09 1995-07-18 Arch Development Corporation Apolipoprotein B MRNA editing protein compositions and methods
KR100356615B1 (ko) 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6235470B1 (en) * 1993-11-12 2001-05-22 The Johns Hopkins University School Of Medicine Detection of neoplasia by analysis of saliva
US6103890A (en) 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
KR0185334B1 (ko) * 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
IT1277025B1 (it) 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
EP0900272A2 (en) 1996-03-26 1999-03-10 Glaxo Group Limited Tumor necrosis factor alpha convertase
EP1164203B1 (en) 1996-11-06 2007-10-10 Sequenom, Inc. DNA Diagnostics based on mass spectrometry
WO1998036641A1 (en) 1997-02-20 1998-08-27 The Schepens Eye Research Institute, Inc. Control of il4 production as a therapeutic regulator of immune function
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
EP2341057A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
GB9721240D0 (en) 1997-10-08 1997-12-03 Zeneca Ltd Assay
US6156315A (en) * 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
EP0911344B1 (en) 1997-10-15 2004-03-03 Fujirebio Inc. Anti-Apo-B-48 monoclonal antibody, hybridoma, and methods of use
DK1049767T3 (da) * 1998-01-08 2005-09-19 Aventis Pharma Inc En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US6949367B1 (en) * 1998-04-03 2005-09-27 Epoch Pharmaceuticals, Inc. Modified oligonucleotides for mismatch discrimination
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
ATE314488T1 (de) 1999-03-18 2006-01-15 Exiqon As Einstufige probezubereitung und bestimmung von nukleinsäure in biologischen proben
CN1361829A (zh) 1999-03-18 2002-07-31 埃克西库恩公司 利用特异性lna引物检测基因突变
US6140124A (en) 1999-04-06 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of P38 mitogen activated protein kinase expression
US20040171566A1 (en) * 1999-04-06 2004-09-02 Monia Brett P. Antisense modulation of p38 mitogen activated protein kinase expression
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US6033910A (en) * 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
AU6910100A (en) 1999-08-18 2001-03-13 Lawrence Chan Apolipoprotein b mrna-specific ribozyme
WO2001030354A1 (en) 1999-10-26 2001-05-03 Thomas Jefferson University REGULATION OF Apob FOR DIAGNOSIS, TREATMENT AND DRUG SCREENING FOR CARDIOVASCULAR AND METABOLIC DISORDERS OR SYNDROMES
AU2911601A (en) * 1999-12-23 2001-07-03 Bristol-Myers Squibb Company Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof
AU2001229501A1 (en) 2000-01-24 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
US20030064950A1 (en) 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
WO2001072765A1 (en) 2000-03-28 2001-10-04 Isis Pharmaceuticals, Inc. ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
EP1268856A2 (de) * 2000-04-07 2003-01-02 Epigenomics AG Detektion von snp's und cytosin-methylierungen
WO2001079555A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US6306655B1 (en) 2000-06-13 2001-10-23 Isis Pharmaceuticals, Inc. Antisense inhibition of C/EBP alpha expression
WO2002024717A1 (en) 2000-09-20 2002-03-28 Isis Pharmaceuticals, Inc. Antisense modulation of flip-c expression
WO2002026768A2 (en) 2000-09-29 2002-04-04 Genaissance Pharmaceuticals, Inc. Haplotypes of the por gene
US20030008373A1 (en) 2001-04-17 2003-01-09 Myriad Genetics, Incorporated APOA1-interacting proteins and use thereof
JP2002355074A (ja) 2001-01-24 2002-12-10 Univ Tsukuba 腸管出血性病原性大腸菌ｏ１５７：ｈ７に特異的な核酸分子およびポリペプチド並びにこれらの使用方法
EP1239051A3 (en) 2001-01-30 2004-03-17 Aeomica, Inc. Human posh-like protein 1
US6660737B2 (en) * 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
US6964950B2 (en) * 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7888324B2 (en) * 2001-08-01 2011-02-15 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7297485B2 (en) * 2001-10-15 2007-11-20 Qiagen Gmbh Method for nucleic acid amplification that results in low amplification bias
EP1481092A4 (en) 2002-03-01 2006-08-09 Ravgen Inc METHODS OF DETECTING GENETIC DISORDERS
JPWO2003097097A1 (ja) 2002-05-15 2005-10-20 洋司郎 新津 Ｖｌａ４アンタゴニストを含む治療用医薬組成物を用いた急性白血病の治療および／または再発予防方法ならびにｖｌａ４を指標とした急性白血病の予後の診断方法
WO2003097662A1 (en) 2002-05-15 2003-11-27 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
EP2336318B1 (en) * 2002-11-13 2013-04-24 Genzyme Corporation Antisense modulation of apolipoprotein b expression
US7511131B2 (en) * 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
AU2003281969B2 (en) 2002-11-18 2011-01-27 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
AU2003218674A1 (en) 2003-02-28 2004-09-17 Edmund John Gemmell Apparatus and method for displaying information
US20040185559A1 (en) * 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US7750142B2 (en) * 2003-04-28 2010-07-06 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
US7825235B2 (en) * 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
WO2005049621A1 (en) 2003-11-13 2005-06-02 Isis Pharmaceuticals, Inc. 5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis
WO2005071080A2 (en) * 2004-01-20 2005-08-04 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US20050287558A1 (en) * 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
HUE026284T2 (en) * 2004-08-10 2016-06-28 Genzyme Corp Oligonucleotides for use in modulating lipoprotein and cholesterol levels in humans
WO2007031081A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-Bl00 EXPRESSION
ES2369328T3 (es) * 2005-09-19 2011-11-29 Isis Pharmaceuticals, Inc. Modulación de la expresión del receptor de glucagón.
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US20070238698A1 (en) * 2006-04-07 2007-10-11 Hsien-Chih Lin Method for manufacturing drinking water having chitosan
AU2007258117B2 (en) * 2006-05-05 2013-05-30 Isis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
KR20150090284A (ko) 2007-03-24 2015-08-05 젠자임 코포레이션 인간 아포리포프로틴 ｂ에 상보적인 안티센스 올리고뉴클레오타이드 투여
EP2408796B1 (en) 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III

Also Published As

Publication number Publication date
AU2008230886B2 (en) 2014-07-31
MX2009010196A (es) 2009-11-18
JP2010522245A (ja) 2010-07-01
US20170096662A1 (en) 2017-04-06
KR20090128494A (ko) 2009-12-15
CN101679979A (zh) 2010-03-24
US9347061B2 (en) 2016-05-24
CO6241170A2 (es) 2011-01-20
CA2682082A1 (en) 2008-10-02
ZA200906772B (en) 2010-12-29
AU2008230886B9 (en) 2014-09-04
AU2008230886A1 (en) 2008-10-02
IL201183A0 (en) 2011-08-01
JP2015007055A (ja) 2015-01-15
WO2008118883A1 (en) 2008-10-02
JP6028142B2 (ja) 2016-11-16
US20100297105A1 (en) 2010-11-25
KR20150090284A (ko) 2015-08-05
CN103480002A (zh) 2014-01-01
BRPI0809320A2 (pt) 2014-09-23
EP2137311A1 (en) 2009-12-30
RU2559536C2 (ru) 2015-08-10
JP2017002061A (ja) 2017-01-05
RU2009139221A (ru) 2011-05-10

Similar Documents

Publication Publication Date Title
RU2015127794A (ru) Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
MA32692B1 (fr) Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
WO2007081975A3 (en) Method of treating multiple sclerosis
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2009102342A5 (ru)
HRP20150375T1 (hr) Derivati piridazinona
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
BR112015010396A2 (pt) terapia de combinação
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
JP2011528333A5 (ru)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
UA105644C2 (ru) Способы лечения легочных нарушений составами липосомального амикацина
JP2011225596A5 (ru)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
RU2012108439A (ru) Способы лечения опухолей головного мозга
JP2016505050A5 (ru)
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
MX2009004579A (es) Composicion farmaceutica que tiene actividad antisicotica, antidepresiva o antiepileptica, con efecto colateral reducido.
JP2017530142A5 (ru)
RU2010122438A (ru) Противовирусное средство для профилактики и лечения клещевого энцефалита

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20180710